《大行》汇丰研究升信达生物(01801.HK)目标价至65.8元 评级“买入”

阿斯达克财经
May 30, 2025

汇丰研究发表报告,指信达生物(01801.HK) 本年至今股价累升约63%,跑赢恒生医疗保健指数同期的32%升幅。其于2025年的美国临床肿瘤学会(ASCO),在黑色素瘤、非小细胞肺癌及大肠癌中显示出令人鼓舞的概念验证,预期将在中国启动更多第三期临床试验,并对IBI343的授权潜力更为乐观;同时预期GLP1/GIP的上市、CLDN18.2抗体偶联药物(ADC)的新药申请提交及业务发展将支持股价...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10